Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06014-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Emilia Scalzulli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Abstract (Originalsprache)
A comprehensive analysis of 220 patients diagnosed with APL between 1993 and 2022 is here reported. Overall, 214 patients (97.2%) received induction therapy. Complete response (CR) was achieved in 97.4%, 100%, 100%, and 27% of patients treated with AIDA protocol, AIDA + Ara-C, ATRA + ATO, and ATRA monotherapy, respectively. Molecular complete response (CR MRD -) was achieved in 96.8% cases, and 142 patients proceeded to maintenance therapy. Overall, the 3-year and 5-year overall survival (OS) rates were 80.8% (95% CI, 78.1–83.5) and 79.1% (95% CI, 76.4–81.8), respectively. Considering only patients who completed induction and maintenance therapy, the 5-year OS rates were 82.1% (95% CI, 77.5–86.7) for the AIDA0493 cohort, 87.5% (95% CI, 84.4–91.1) for the AIDA2000 cohort, and 100% for the APL0406 cohort ( p = 0.044). Additionally, the disease-free survival (DFS) rates were 65.7% (95% CI, 60.4–70.9), 70% (95% CI, 65.8–75.2), and 95.1% (95% CI, 91.7–98.5) ( p = 0.016), respectively. Among low and intermediate-risk patients, age > 70 years ( p = 0.027) and relapse ( p < 0.001) were significantly associated with reduced outcomes. This study contributes to the advancement of our understanding of APL treatment, underscoring the ongoing need for research to enhance outcomes and explore new therapeutic approaches and prognostic factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
- Hematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Sardegna, Italy.
- Hematology Unit, Belcolle Hospital, Viterbo, Italy.
- Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy. breccia@bce.uniroma1.it.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Scalzulli, E., Costa, A., Carmosino, I., Musiu, P., Bisegna, M. L., De Propris, M. S., Ielo, C., Diverio, D., Minotti, C., Capria, S., Latagliata, R., Martelli, M., & Breccia, M. (2024). Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time. Annals of Hematology. https://doi.org/10.1007/s00277-024-06014-1
Vancouver
Scalzulli E, Costa A, Carmosino I, Musiu P, Bisegna ML, De Propris MS, et al. Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time. Annals of Hematology. 2024. doi:10.1007/s00277-024-06014-1
BibTeX
@article{Scalzulli2024,
author = {Scalzulli, Emilia and Costa, Alessandro and Carmosino, Ida and Musiu, Paolo and Bisegna, Maria Laura and De Propris, Maria Stefania and Ielo, Claudia and Diverio, Daniela and Minotti, Clara and Capria, Saveria and Latagliata, Roberto and Martelli, Maurizio and Breccia, Massimo},
title = {Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06014-1}
}
EUVIMED